This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

atogepant in acute migraine

Authoring team

Atogepant is a CGRP receptor antagonist.

NICE have stated that atogepant can be used as an option for the acute treatment of migraine with or without aura in adults, only if, for previous migraines (1):

  • at least 2 triptans were tried and they did not work well enough, or
  • triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough

The NICE committee note:

  • “ ..Rimegepant is the usual acute treatment for migraine after at least 2 triptans have not worked well enough, or if people cannot have triptans, and NSAIDs and paracetamol do not work well enough…Clinical trial evidence shows that atogepant is more effective than placebo. It has not been directly compared in a clinical trial with rimegepant. Evidence from an indirect comparison suggests that the levels of pain reduction at 2 hours are similar with atogepant and rimegepant. But these results are uncertain. This means that it is unclear from these results alone whether atogepant works the same as, or better or less well than, rimegepant. But, because the way the medicines work and are administered are similar, it is likely that their clinical effectiveness is similar…”

Reference:

  1. NICE (June 2026). Atogepant for treating migraine

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.